2241664-16-2
2241664-16-2 structure
- Name: JNJ4796
- Chemical Name: JNJ4796
- CAS Number: 2241664-16-2
- Molecular Formula: C28H27N9O3
- Molecular Weight: 537.57
- Catalog: Signaling Pathways Anti-infection Influenza Virus
- Create Date: 2019-06-01 18:46:56
- Modify Date: 2024-01-13 20:36:16
-
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1].
| Name | JNJ4796 |
|---|
| Description | JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1]. |
|---|---|
| Related Catalog | |
| Target |
EC50: 12 nM (H1/Bris), 66 nM (H1/Cal), 38 nM (H1/NCa), 22 nM (H1/PR8), 13 nM (H1/SI06), 449 nM (H5/H97), 3.24 μM (H5/Viet)[1]. Hemagglutinin[1]. |
| In Vitro | Like bnAb CR6261, the mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell[1]. |
| In Vivo | Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved[1]. Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD90), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1]. Animal Model: Female BALB/cAnNCrl mice intranasally infected with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34 dissolved in sterile phosphate buffered saline (D-PBS)[1] Dosage: 50 and 10 mg/kg. Administration: Oral twice daily for 7 days. Result: Resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897. |
| References |
| Molecular Formula | C28H27N9O3 |
|---|---|
| Molecular Weight | 537.57 |